Literature DB >> 6801214

Increased serum phospholipids in epileptic children treated with phenobarbitone.

L Pavone, G Klose, F Mollica, M La Rosa, H Greten.   

Abstract

Plasma lipid concentration and post-heparin lipolytic activity in twenty-two epileptic children treated either with phenobarbitone or sodium valproate were evaluated. An increase of phospholipid was observed in whole blood as well as in the low-density nd high-density lipoproteins in patients undergoing phenobarbitone treatment. No change was found in subjects treated with sodium valproate. The enzyme activities were slightly, but not statistically significantly, increased in the two groups compared with the control subjects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6801214      PMCID: PMC491271          DOI: 10.1136/jnnp.45.1.81

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  Increase in serum cholesterol during phenytoin treatment.

Authors:  R Pelkonen; R Fogelholm; E A Nikkilä
Journal:  Br Med J       Date:  1975-10-11

2.  The quantitative histochemistry of brain. I. Chemical methods.

Authors:  O H LOWRY; N R ROBERTS; K Y LEINER; M L WU; A L FARR
Journal:  J Biol Chem       Date:  1954-03       Impact factor: 5.157

3.  Elevation of high-density lipoprotein in epileptic patients treated with phenytoin.

Authors:  E A Nikkilä; M Kaste; C Ehnholm; J Viikari
Journal:  Acta Med Scand       Date:  1978

4.  Chronic antiepileptic toxicity: a review.

Authors:  E H Reynolds
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

5.  Letter: Phenytoin and serum cholesterol.

Authors:  S Livingston
Journal:  Br Med J       Date:  1976-03-06

6.  Measurement of two plasma triglyceride lipases by an immunochemical method: studies in patients with hypertriglyceridemia.

Authors:  H Greten; R DeGrella; G Klose; W Rascher; J L de Gennes; E Gjone
Journal:  J Lipid Res       Date:  1976-05       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.